Targeting the kinesin spindle protein: Basic principles and clinical implications

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7583-7587

  Sarli, Vasiliki ^a   Giannis, Athanassios ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOCIASULFATE 2; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ARRY 520; CAPECITABINE; CISPLATIN; CK 0106023; DIHYDROPYRAZOLE DERIVATIVE; DIHYDROPYRROLE DERIVATIVE; DIMETHYLENASTRON; GSK 1; GSK 2; HR 22C16; ISPINESIB; KINESIN; KINESIN SPINDLE PROTEIN; MK 0731; MONASTROL; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PYRROLE DERIVATIVE; S TRITYLCYSTEINE; SB 743921; TERPENDOLE E; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; KIF11 PROTEIN, HUMAN;

ANEMIA; BREAST CANCER; CELL CYCLE ARREST; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK CARCINOMA; HIGH THROUGHPUT SCREENING; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LYMPHATIC LEUKEMIA; MELANOMA; MICROTUBULE ASSEMBLY; MITOSIS; MONOTHERAPY; MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; KINESIN; NEOPLASMS;

EID: 59449102892     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0120     Document Type: Review

References (53)

1. Chabner BA, Amrein PC Druker, et al. Antineoplastic agents. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. McGraw-Hill, New York; 2006.
2. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72.
3. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4.
4. Vale RD, Fletterick RJ. The design plan of kinesin motors. Annu Rev Cell Dev Biol 1997;13:745-77.
5. Kapitein LC, Peterman EJG,Kwok BH,et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435:114-8.
6. Cameron LA Yang G,Cimini D,etal. Kinesin5-independent poleward flux of kinetochore microtubules in PtK1 cells. J Cell Biol 2006;173:173-9.
7. Valentine MT, Fordyce PM, KrzysiakTC, et al. Individual dimers of the mitotic kinesin motor Eg5 step processively and support substantial loads in vitro. Nat Cell Biol 2006;8:470-6.
8. Kashina AS, Baskin RJ, Cole DG, et al. A bipolar kinesin. Nature1996;379:270-2.
9. Cole DG, Saxton WM, Sheehan KB, et al. A ''slow'' homotetrameric kinesin-related motor protein purified from Drosophila embryos. J Biol Chem 1994;269:22913-6.
10. Sawin KE, LeGuellec K, Philippe M, et al. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature1992;359:540-3.
11. BlangyA, Lane HA, d'Herin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69.
12. Weil D, Garcon L, Harper M, et al. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques 2002;33:1244-8.
13. Chabner BA, Amrein, PC Druker, et al. Antineoplastic agents. In: Brunton LL, LazoJS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. McGraw-Hill, NewYork; 2006.
14. Mayer TU, Kapoor TM, Haggarty SJ, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4.
15. Yan Y, Sardana V, Xu B, et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 2004;335:547-54.
16. Gartner M, Sunder-Plassmann N, SeilerJ, et al. De velopment and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5. Chembio-chem 2005;6:1173-7.
17. Sarli V, Huemmer S, Sunder-Plassmann N, et al. Synthesis and biological evaluation of novel EG5 inhibitors. Chembiochem 2005;6:2005-13.
18. Sakowicz R,Berdelis MS,Ray K,et al.Amarinenatural product inhibitor of kinesin motors. Science1998;280:292-5.
19. Nakazawa J, Yajima J, Usui T, et al. A novel action of terpendole E on the motor activity of mitotic kinesin Eg5. Chem Biol 2003;10:131-7.
20. Hotha S,YarrowJC,Yang JG, et al. HR22C16: a potent small-molecule probe for the dynamics of cell division. AngewChem Int Ed Engl 2003;42:2379-82.
21. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
22. Cox CD, Breslin MJ, Mariano BJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3, 5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2005;15:2041-5.
23. DeBonis S, Skoufias D, Robin G, et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 2004;3:1079-90.
24. Tao W,South VJ,Zhang Y, et al.Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
25. Rickert KW, Schaber M,Torrent M, et al. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 2008;469:220-31.
26. Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005;5:127-45.
27. Sarli V, Giannis A. Inhibitors of mitotic kinesins: next-generation antimitotics. Chem Med Chem 2006;13:293-8.
28. Parrish CA, Adams ND, Auger KR, et al. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 2007;50:4939-52.
29. Luo L, Parrish CA, Nevins N, et al. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 2007;3:722-6.
30. Brier S, Carletti E, DeBonis S, et al. The marine natural product adociasulfate-2 as a tool to identify the MT-binding region of kinesins. Biochemistry 2006;45:15644-53.
31. Leizerman I, Avunie-Masala R, ElkabetsM, et al. Differential effects of monastrol in two human cell lines. Cell Mol Life Sci 2004;61:2060-70.
32. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
33. Tao W,South VJ,Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol2007;27:689-98.
34. Chin GM, Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol CancerTher 2006;5:2580-91.
35. Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67:237-45.
36. Liu M, Aneja R, Liu C, et al. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidy linositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006;281:18090-7.
37. Johnson RK, McCabe FL, Cauder E, et al. SB-715992, a potent and selective inhibitor ofKSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002;43:269.
38. Burris HA, Lorusso P, Jones S, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB- 715992 IV days 1, 8,15 q 28 days (this is an abstract, only one page). J Clin Oncol 2004;22:2004.
39. Heath EI, Alouisi A, Eder JP, et al. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2006 24:A2026.
40. Chu QS, Holen KD, Rowinsky EK, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Am Soc Clin Oncol 2004;22:A2078.
41. Miller K, Ng C, Ang P, et al. PTC phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer. Breast Cancer ResTreat 2005;94 (suppl 1): abstract1089.
42. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 2007;12:375-89.
43. Knox JJ, Gill S, Synold TW, et al. A phase II and pharmacokinetic studyof SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest NewDrugs 2008; 26:265-72.
44. Lee CW, Belanger K, Rao SC, et al. Phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008;26:249-55.
45. Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008;26:257-64.
46. El-KhoueiryAB,IqbalS,SinghDA,et al.Arandomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic co- lorectal cancer. A California Cancer Consortium Study (CCC-P). ASCO Annual Meeting Proceedings 2006, Part I 24 (18S) Invest New Drugs: abstract 3595.
47. 47.Beekman KW, Dunn R, et al. University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings Part I 25(18S): abstract15573.
48. Calvo E, Chu Q,Til E,et al. PhaseI study of ispinesib in combination with capecitabine in patients with advanced solid tumors. AACR-NCI-EORTC, November 2005.
49. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
50. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008;83:673-91.
51. Jackson JR, Auger KR, Gilmartin A, et al. A resistance mechanism for the KSP inhibitor Ispinesib implicates point mutations in the compound-binding site. Poster Meeting C207, AACR-NCI-EORTC International Conference on Molecular Target in Cancer Therapeutics: Discovery, Biology and Clinical Applications, November14-18, 2005; Philadelphia.
52. Valentine MT, Fordyce PM, Block SM. Eg5 steps it up! Cell Div 2006;1:31.
53. Albers B, et al. Molecular biology of the cell.Walter, 4th ed. Garland Science; 2002. p. 1037.